First Interstate Bank cut its stake in GlaxoSmithKline plc (NYSE:GSK) by 54.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 787 shares of the pharmaceutical company’s stock after selling 935 shares during the quarter. First Interstate Bank’s holdings in GlaxoSmithKline were worth $33,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in GSK. Boston Partners purchased a new position in shares of GlaxoSmithKline in the 4th quarter valued at $65,234,000. Morgan Stanley increased its holdings in shares of GlaxoSmithKline by 16.5% in the 3rd quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock valued at $169,232,000 after acquiring an additional 597,367 shares during the period. Norges Bank purchased a new position in shares of GlaxoSmithKline in the 4th quarter valued at $17,275,000. Two Sigma Investments LP purchased a new position in shares of GlaxoSmithKline in the 4th quarter valued at $15,936,000. Finally, Deutsche Bank AG increased its holdings in shares of GlaxoSmithKline by 221.0% in the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after acquiring an additional 364,431 shares during the period. Institutional investors and hedge funds own 11.11% of the company’s stock.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 325,000 shares of the stock in a transaction dated Monday, April 22nd. The stock was purchased at an average price of $18.00 per share, with a total value of $5,850,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is owned by company insiders.
GlaxoSmithKline stock opened at $39.74 on Thursday. The company has a quick ratio of 0.48, a current ratio of 0.72 and a debt-to-equity ratio of 6.92. The firm has a market capitalization of $99.60 billion, a PE ratio of 12.58, a price-to-earnings-growth ratio of 2.11 and a beta of 0.74. GlaxoSmithKline plc has a 1-year low of $36.41 and a 1-year high of $42.36.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 6th. The pharmaceutical company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.09. The firm had revenue of $10.55 billion during the quarter, compared to analysts’ expectations of $9.85 billion. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%. As a group, equities research analysts expect that GlaxoSmithKline plc will post 2.92 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a $0.4953 dividend. The ex-dividend date is Thursday, May 16th. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.99%. GlaxoSmithKline’s payout ratio is 75.32%.
A number of research analysts have recently issued reports on the company. UBS Group downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Tuesday, April 23rd. Shore Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. BNP Paribas cut GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. Finally, Exane BNP Paribas cut GlaxoSmithKline from an “outperform” rating to a “neutral” rating in a research report on Monday, January 14th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $41.83.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: Cost of Debt
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.